HFG Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-2,660
Closed -$229K 100
2024
Q4
$229K Hold
2,660
0.2% 82
2024
Q3
$317K Hold
2,660
0.28% 66
2024
Q2
$380K Sell
2,660
-540
-17% -$71.6K 0.35% 53
2024
Q1
$411K Sell
3,200
-126
-4% -$15K 0.36% 61
2023
Q4
$344K Buy
3,326
+500
+18% +$49.4K 0.33% 61
2023
Q3
$257K Buy
+2,826
New +$249K 0.28% 74

Other funds holding NVO

HFG Advisors's NVO Position: Q1 2025 in Review

HFG Advisors sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 2,660 shares — an estimated $229K sold.

HFG Advisors first reported a position in NVO in Q3 2023 and held it in 6 quarters. The position peaked at $411K in Q1 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • HFG Advisors reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • HFG Advisors sold 2,660 Novo Nordisk shares in Q1 2025, an estimated $229K.
  • HFG Advisors first reported a position in Novo Nordisk in Q3 2023 and held it in 6 quarters.
  • HFG Advisors's Novo Nordisk position peaked at $411K in Q1 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on HFG Advisors's 13F filing for Q1 2025, filed 21 Apr 2025.